Delivery Order SPE2DB20D1004-SPE2DB24FF4C0
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $11,527.38 Firm Fixed Price Delivery Order covers the supply of Otezla 30 mg tablets for the DLA Troop Support Medical program. The contract has an ultimate completion date of April 26, 2022. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle...
- This federal contract award is from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $4,900.52 delivery order is for the pharmaceutical product Otezla 30mg Tablet 60s. The contract is a firm fixed-price Delivery Order with an ultimate completion date of April 2, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026. This IDC...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $12,072.45, is for the delivery of Otezla 30 mg tablets. This delivery order is part of Amerisourcebergen's $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for the company to provide a comprehensive range of pharmaceutical...
- This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The $4,690.56 firm-fixed-price delivery order is for the provision of Otezla 30 mg tablets. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 2025, which serves as the primary vehicle for the company to deliver a range of...
- This contract award, valued at $32,404.47, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a pharmaceutical distribution company. The award provides for the delivery of Otezla 30 mg tablets under a firm-fixed-price delivery order contract. The contract has an ultimate completion date of April 29, 2024. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $78,887.83, is for the delivery of Otezla 30 mg tablets. This IDC, valued up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $15,565.37, is for the delivery of Otezla 30 mg tablets to support military healthcare programs. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This $999,999,999 IDC serves as the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Otezla 30 mg tablets. The contract, valued at $60,126.75, is a Firm Fixed Price Delivery Order with a completion date of May 3, 2023. The award is not set-aside and was made through full and open competition. Amerisourcebergen Drug Corp has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $33,290.72 firm fixed-price delivery order is for the supply of Otezla 30 mg tablets. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a wide range...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $19,948.07, is for the delivery of Otezla 30 mg tablets. The contract is a delivery order with a firm fixed price and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB24FF4C0Delivery Order
This federal contract award, valued at $4,357.49, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Otezla 30 mg tablets in quantities of 60 to support government healthcare programs. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which runs through November 2026. This single-award IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs demonstrate Amerisourcebergen's capacity to meet the diverse and critical pharmaceutical needs of multiple government agencies on a large scale. The contract award does not have a set-aside designation, indicating it was awarded through full and open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 2/12/24 |